Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost-effectiveness as a price control.

Anupam B Jena1, Tomas Philipson

  • 1Department of Economics and School of Medicine, University of Chicago, Illinois, USA. ajena@uchicago.edu

Health Affairs (Project Hope)
|May 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Newborn Hepatitis B Virus Vaccination-Reply.

JAMA·2026
Same author

Pediatric Influenza Vaccination Efficacy.

JAMA pediatrics·2026
Same author

Rates of Leucovorin Prescriptions for Children With Autism.

JAMA network open·2026
Same author

Suicide Mortality Among Adolescents and Young Adults After Launch of a Suicide and Crisis Lifeline.

JAMA·2026
Same author

Association of Speed Camera Enforcement With Motor Vehicle Crash Injuries.

Annals of surgery·2026
Same author

US Newborn Hepatitis B Virus Vaccination Rates.

JAMA·2026
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Cost-effectiveness analysis for technology adoption often overlooks innovation incentives. Higher prices for new technologies balance current patient welfare against future patient benefits from R&D. A case study on HIV/AIDS illustrates this trade-off.

Area of Science:

  • Health Economics
  • Technology Adoption
  • Pharmaceutical Innovation

Background:

  • Cost-effectiveness analysis (CEA) is crucial for technology adoption decisions.
  • Existing CEA frameworks often neglect the impact on research and development (R&D) incentives.
  • This oversight can affect the introduction of new medical technologies.

Purpose of the Study:

  • To analyze the role of technology adoption procedures in incentivizing innovation.
  • To examine the trade-off between current patient welfare (via prices) and future patient welfare (via innovation).
  • To illustrate these economic principles with a case study.

Main Methods:

  • Economic modeling of R&D incentives within technology adoption frameworks.
  • Analysis of the relationship between pricing, innovation, and patient welfare.

Related Experiment Videos

  • Empirical case study of HIV/AIDS technologies.

    • Main Results:

    • Technology adoption decisions influence R&D by setting price points.
    • Higher prices can incentivize innovation, benefiting future patients.
    • This creates a welfare trade-off between current and future patient populations.

    Conclusions:

    • Adoption procedures must account for R&D incentives to balance economic and health outcomes.
    • The study highlights the complex interplay between pricing, innovation, and patient welfare in healthcare.
    • A nuanced approach to CEA is needed to foster sustainable medical innovation.